Beijing Tiantan Biological Products Co., Ltd. (SHA: 600161)
China flag China · Delayed Price · Currency is CNY
23.74
-0.20 (-0.84%)
Sep 6, 2024, 3:00 PM CST

Beijing Tiantan Biological Products Ratios and Metrics

Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year
CurrentFY 2023 FY 2022 FY 2021 FY 2020 FY 2019 2018 - 2014
Period Ending
Sep '24 Dec '23 Dec '22 Dec '21 Dec '20 Dec '19 2018 - 2014
Market Capitalization
46,94350,98339,10339,76752,31029,208
Upgrade
Market Cap Growth
7.84%30.38%-1.67%-23.98%79.10%57.78%
Upgrade
Enterprise Value
45,20549,02337,84637,74452,38429,158
Upgrade
Last Close Price
23.7425.6519.6419.8928.5615.93
Upgrade
PE Ratio
37.2245.9544.4650.7880.7346.80
Upgrade
PS Ratio
8.859.849.189.6715.188.90
Upgrade
PB Ratio
4.554.003.443.878.675.64
Upgrade
P/FCF Ratio
39.6838.74-171.49-262.76561.25251.27
Upgrade
P/OCF Ratio
20.7221.3034.7340.5674.5045.46
Upgrade
EV/Sales Ratio
8.489.468.889.1815.208.88
Upgrade
EV/EBITDA Ratio
20.1625.1226.0728.7544.3325.36
Upgrade
EV/EBIT Ratio
23.1928.7329.2732.1549.9428.55
Upgrade
EV/FCF Ratio
38.2137.25-165.98-249.39562.04250.85
Upgrade
Debt / Equity Ratio
0.000.000.040.050.130.08
Upgrade
Debt / EBITDA Ratio
0.020.020.270.380.680.35
Upgrade
Debt / FCF Ratio
0.040.03-1.77-3.368.593.45
Upgrade
Asset Turnover
0.370.380.350.430.500.58
Upgrade
Inventory Turnover
0.890.990.971.000.850.91
Upgrade
Quick Ratio
3.203.664.256.642.623.18
Upgrade
Current Ratio
5.225.926.289.324.966.21
Upgrade
Return on Equity (ROE)
13.52%12.52%11.14%13.12%16.83%18.78%
Upgrade
Return on Assets (ROA)
8.40%7.86%6.60%7.68%9.46%11.22%
Upgrade
Return on Capital (ROIC)
9.43%8.69%7.17%8.33%10.56%12.57%
Upgrade
Earnings Yield
2.69%2.18%2.25%1.91%1.22%2.09%
Upgrade
FCF Yield
2.52%2.58%-0.58%-0.38%0.18%0.40%
Upgrade
Dividend Yield
0.53%0.49%0.21%0.35%0.24%0.22%
Upgrade
Payout Ratio
26.27%8.47%17.85%21.56%14.54%9.88%
Upgrade
Buyback Yield / Dilution
-0.45%0.32%-2.79%-7.41%-0.59%0.04%
Upgrade
Total Shareholder Return
0.07%0.81%-2.58%-7.06%-0.35%0.26%
Upgrade
Source: S&P Capital IQ. Standard template. Financial Sources.